Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2007

01-02-2007 | Original Article

Predictors and Noninvasive Identification of Severe Liver Fibrosis in Patients with Chronic Hepatitis C

Authors: Mohamed A. Metwally, Claudia O. Zein, Nizar N. Zein

Published in: Digestive Diseases and Sciences | Issue 2/2007

Login to get access

Abstract

Diagnosis of severe fibrosis (stages III and IV) in hepatitis C has clinical implications. Our objective was to distinguish independent predictors of severe fibrosis and use them to identify patients with severe fibrosis without a liver biopsy. One hundred ninety-nine hepatitis C patients were included in the initial analysis to identify predictors of severe fibrosis. Univariate and multivariate analyses of 26 predetermined variables for significance in predicting severe fibrosis were performed. Based on the coefficient regression and P values, a scoring system was developed and applied to a second independent cohort (137 patients) for validation. In multivariate analysis, low platelet count, low albumin, aspartate transaminase level, history of blood transfusion, and hepatitis B core antibody were significant independent predictors of severe fibrosis. A scoring system (range, 0–9) was developed from the three variables with the lowest P values (platelet count, aspartate transaminase, and albumin). A cutoff point of 4 had 99% specificity and 94% positive predictive value. A cutoff point of 2 had 87% sensitivity and 95% negative predictive value. We conclude that severe fibrosis in hepatitis C may potentially be identified with a high degree of certainty in a substantial number of patients with a simple noninvasive scoring system.
Literature
1.
go back to reference WHO/Viral Hepatitis Prevention Board (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6:35–47CrossRef WHO/Viral Hepatitis Prevention Board (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6:35–47CrossRef
2.
go back to reference Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562PubMedCrossRef Alter MJ, Kruszon-Moran D, Nainan OV, et al. (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556–562PubMedCrossRef
3.
go back to reference Alter MJ (1995) Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5–14PubMed Alter MJ (1995) Epidemiology of hepatitis C in the West. Semin Liver Dis 15:5–14PubMed
4.
go back to reference Terrault N, Wright T (1995) Interferon and hepatitis C virus infection. N Engl J Med 332:1509–1511PubMedCrossRef Terrault N, Wright T (1995) Interferon and hepatitis C virus infection. N Engl J Med 332:1509–1511PubMedCrossRef
5.
go back to reference Di Bisceglie AM (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31:1014–1018PubMedCrossRef Di Bisceglie AM (2000) Natural history of hepatitis C: its impact on clinical management. Hepatology 31:1014–1018PubMedCrossRef
6.
go back to reference Kiyosawa K, Sodeyama T, Tanaka E, et al. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMed Kiyosawa K, Sodeyama T, Tanaka E, et al. (1990) Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675PubMed
7.
go back to reference Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an “a la carte” combination interferon alfa-2b plus ribavirinregimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211–218PubMedCrossRef Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J (2000) Is an “a la carte” combination interferon alfa-2b plus ribavirinregimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31:211–218PubMedCrossRef
8.
go back to reference Khan MH, Thomas L, Byth K, et al. (1998) How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 13:419–426PubMed Khan MH, Thomas L, Byth K, et al. (1998) How much does alcohol contribute to the variability of hepatic fibrosis in chronic hepatitis C? J Gastroenterol Hepatol 13:419–426PubMed
9.
go back to reference Hourigan LF, Macdonald GA, Purdie D, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219PubMedCrossRef Hourigan LF, Macdonald GA, Purdie D, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215–1219PubMedCrossRef
10.
go back to reference Bonacini M, Hadi G, Govindarajan S, Lindsay KL (1997) Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92:1302–1304PubMed Bonacini M, Hadi G, Govindarajan S, Lindsay KL (1997) Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 92:1302–1304PubMed
11.
go back to reference Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K (2001) The role of liver biopsy in chronic hepatitis C. Hepatology 33:196–200PubMedCrossRef Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K (2001) The role of liver biopsy in chronic hepatitis C. Hepatology 33:196–200PubMedCrossRef
12.
go back to reference Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069–1075PubMedCrossRef Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T, MULTIVIRC Group (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069–1075PubMedCrossRef
13.
go back to reference Wannamethee G, Shaper AG (1988) Men who do not drink: a report from the British Regional Heart Study. Int J Epidemiol 17:307–316PubMedCrossRef Wannamethee G, Shaper AG (1988) Men who do not drink: a report from the British Regional Heart Study. Int J Epidemiol 17:307–316PubMedCrossRef
14.
go back to reference Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125:634–639PubMed Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125:634–639PubMed
15.
go back to reference The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20CrossRef The French METAVIR Cooperative Study Group (1994) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20:15–20CrossRef
16.
go back to reference Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293PubMedCrossRef Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289–293PubMedCrossRef
17.
go back to reference Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed
18.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470PubMedCrossRef Kamath PS, Wiesner RH, Malinchoc M, et al. (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33:464–470PubMedCrossRef
19.
go back to reference Lechner K, Niessner H, Thaler E (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4:40–56PubMed Lechner K, Niessner H, Thaler E (1977) Coagulation abnormalities in liver disease. Semin Thromb Hemost 4:40–56PubMed
20.
go back to reference Aoki Y, Hirai K, Tanikawa K (1993) Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 20:123–129PubMedCrossRef Aoki Y, Hirai K, Tanikawa K (1993) Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 20:123–129PubMedCrossRef
21.
go back to reference de Noronha R, Taylor BA, Wild G, Triger DR, Greaves M (1991) Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease. Clin Lab Haematol 13:127–135PubMedCrossRef de Noronha R, Taylor BA, Wild G, Triger DR, Greaves M (1991) Inter-relationships between platelet count, platelet IgG, serum IgG, immune complexes and severity of liver disease. Clin Lab Haematol 13:127–135PubMedCrossRef
22.
go back to reference Sheth SG, Flamm SL, Gordon FD, Chopra S (1998) AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93:44–48PubMedCrossRef Sheth SG, Flamm SL, Gordon FD, Chopra S (1998) AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 93:44–48PubMedCrossRef
23.
go back to reference De Maria N, Colantoni A, Friedlander L, et al. (2000) The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95:3529–3536PubMedCrossRef De Maria N, Colantoni A, Friedlander L, et al. (2000) The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 95:3529–3536PubMedCrossRef
24.
go back to reference Gordon SC, Elloway RS, Long JC, Dmuchowski CF (1993) The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18:1338–1343PubMedCrossRef Gordon SC, Elloway RS, Long JC, Dmuchowski CF (1993) The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 18:1338–1343PubMedCrossRef
Metadata
Title
Predictors and Noninvasive Identification of Severe Liver Fibrosis in Patients with Chronic Hepatitis C
Authors
Mohamed A. Metwally
Claudia O. Zein
Nizar N. Zein
Publication date
01-02-2007
Published in
Digestive Diseases and Sciences / Issue 2/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9366-z

Other articles of this Issue 2/2007

Digestive Diseases and Sciences 2/2007 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.